ReviewFrontiers in medicine2026
Advances in AI-based diagnosis of Alzheimer's disease using MRI: a comprehensive survey.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI), especially Deep Learning (DL), has been shown significant in accelerating the detection and diagnosis of neurological disorders via medical imaging. This study is mainly focused on Alzheimer's disease (AD), which reveals distinctive structural modifications observable by Magnetic Resonance Imaging (MRI). Although several studies employing convolutional neural networks (CNNs) and other artificial intelligence models indicate promising diagnostic accuracy, many issues related to methodology exist. This research offers a comprehensive assessment of recent studies (2000-2025) to synthesize the key limitations limiting the clinical application of AI for AD detection using MRI. The study identify the main challenges, namely: (1) restricted access to extensive, curated, and diverse multimodal datasets; (2) elevated model complexity with associated risks of overfitting on small cohorts; (3) insufficient interpretability and clinical validation of AI decisions; (4) computational inefficiency and excessive energy consumption; and (5) challenges in generalizing models across heterogeneous cohorts and imaging guidelines. Our study indicates that modern research frequently emphasizes marginal improvements in accuracy rather than solving these essential translational obstacles. The authors conclude by outlining essential research progressions, highlighting the necessity for federated learning for dealing with data scarcity, the advancement of explainable AI (XAI) frameworks, and the creation of standardized benchmarking protocols to flexible, clinically-adoptable AI methods for early AD detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.